STEMI 患者血浆和血小板 CCL2 水平及其对血小板 NF-κB 信号通路的影响.

Objective: To study the expressions of chemokine CCL2 in the plasma and the platelets of patients with STEMI, and investigate the effect of CCL2 on P65 and IκBα of the platelets. Methods: 50 patients with STEMI who were admitted in the CCU of General Hospital of Shenyang Military Region from October 2015 to January 2016 and 50 healthy controls were enrolled. The plasma CCL2 concentration of patients with STEMI and healthy controls were detected by ELISA. The expressions of CCL2 and CCR2 in the platelets were detected by western blot; the phosphorylation of P65 and IκBα in the platelets were tested by western blot after CCL2 stimulation, or while CCR2 antagonist RS201895 and NF-κB signaling pathway inhibitor Bayl 1-7082 were pretreated on the platelets. Results: The plasma CCL2 concentration of STEMI patients and healthy controls were 222± 98 pg/mL and 162± 24 pg/mL, there were significant statistical differences between the two groups (P＜0.01). Compared with control group, the expression of CCL2 and CCR2 in the platelets were significantly increased in STEMI patients (P＜0.01). After the platelets were stimulated by CCL2, pP65 increased and IκBα decreased (P＜0.01); when RS201895 or Bay 11-7082 treated before CCL2 stimulation, the phosphorylation of P65 decreased and IκBα increased (P＜0.01). Conclusions: The expression of CCL2 in plasma and platelets of patients with STEMI increased. CCL2/CCR2 might affect the functions of platelets through NF-κB signaling pathway and participate in the thrombosis. [ABSTRACT FROM AUTHOR]